Deucravacitinib Shows Durable Efficacy in Psoriasis Over 2 Years, finds study
Researchers have found in a new study that in a real-world Japanese cohort, deucravacitinib 6 mg provided sustained disease control in patients with moderate-to-severe psoriasis over 104 weeks. Treatment responses…